These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18366243)

  • 1. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study.
    Avins AL; Manos MM; Ackerson L; Zhao W; Murphy R; Levin TR; Watson DJ; Hwang PM; Replogle A; Levine JG
    Drug Saf; 2008; 31(4):325-34. PubMed ID: 18366243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.
    Vuppalanchi R; Teal E; Chalasani N
    Am J Med Sci; 2005 Feb; 329(2):62-5. PubMed ID: 15711421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining patient risks from expanded preventive therapies.
    Tolman KG
    Am J Cardiol; 2000 Jun; 85(12A):15E-9E. PubMed ID: 10858489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of statins: effects on muscle and the liver.
    Vasudevan AR; Hamirani YS; Jones PH
    Cleve Clin J Med; 2005 Nov; 72(11):990-3, 996-1001. PubMed ID: 16315438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
    Frisinghelli A; Mafrici A
    Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART).
    Elkind MS; Sacco RL; Macarthur RB; Peerschke E; Neils G; Andrews H; Stillman J; Corporan T; Leifer D; Liu R; Cheung K
    Cerebrovasc Dis; 2009; 28(3):266-75. PubMed ID: 19609078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin.
    Dujovne CA; Chremos AN; Pool JL; Schnaper H; Bradford RH; Shear CL; Higgins J; Downton M; Franklin FA; Nash DT
    Am J Med; 1991 Jul; 91(1B):25S-30S. PubMed ID: 1831006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
    Strauss WE; Lapsley D; Gaziano JM
    Am Heart J; 1999 Mar; 137(3):458-62. PubMed ID: 10047626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.
    Chalasani N; Aljadhey H; Kesterson J; Murray MD; Hall SD
    Gastroenterology; 2004 May; 126(5):1287-92. PubMed ID: 15131789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin use in patients with elevated serum hepatic transaminases at baseline: A meta-analysis.
    Masson W; Lobo M; Masson G; Molinero G; Casciato P
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1357-1364. PubMed ID: 33715945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential hepatoprotective effects of lovastatin combined with oral hypoglycemic agents in streptozotocin-induced diabetes in rats.
    Sharkawi SMZ; El-Shoura EAM; Abo-Youssef AM; Hemeida RAM
    Immunopharmacol Immunotoxicol; 2020 Apr; 42(2):165-173. PubMed ID: 32114843
    [No Abstract]   [Full Text] [Related]  

  • 13. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice.
    Kim H; Lee H; Kim TM; Yang SJ; Baik SY; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
    Cardiovasc Ther; 2018 Jun; 36(3):e12324. PubMed ID: 29464863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
    Tzefos M; Olin JL
    J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
    Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
    Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and long-term adverse effect pattern of lovastatin.
    Tobert JA
    Am J Cardiol; 1988 Nov; 62(15):28J-34J. PubMed ID: 3055921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.
    Segarra-Newnham M; Parra D; Martin-Cooper EM
    Pharmacotherapy; 2007 Jun; 27(6):845-51. PubMed ID: 17542767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
    Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients.
    Pai GS; Khan M; Barbosa E; Key LL; Craver JR; Curé JK; Betros R; Singh I
    Mol Genet Metab; 2000 Apr; 69(4):312-22. PubMed ID: 10870849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.